These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 33800934)
1. Advanced Therapy Medicinal Products for the Eye: Definitions and Regulatory Framework. López-Paniagua M; de la Mata A; Galindo S; Blázquez F; Calonge M; Nieto-Miguel T Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33800934 [TBL] [Abstract][Full Text] [Related]
2. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211 [TBL] [Abstract][Full Text] [Related]
3. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215 [TBL] [Abstract][Full Text] [Related]
4. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Iglesias-Lopez C; Obach M; Vallano A; Agustí A Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292 [TBL] [Abstract][Full Text] [Related]
5. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand. Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851 [TBL] [Abstract][Full Text] [Related]
6. Advanced therapy medicinal products: current and future perspectives. Hanna E; Rémuzat C; Auquier P; Toumi M J Mark Access Health Policy; 2016; 4():. PubMed ID: 27123193 [TBL] [Abstract][Full Text] [Related]
7. The Current State of Advanced Therapy Medicinal Products in the Czech Republic. Kočí Z; Boráň T; Krůpa P; Kubinová Š Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533 [TBL] [Abstract][Full Text] [Related]
8. European regulatory tools for advanced therapy medicinal products. Flory E; Reinhardt J Transfus Med Hemother; 2013 Dec; 40(6):409-12. PubMed ID: 24474890 [TBL] [Abstract][Full Text] [Related]
9. Advanced therapy medicinal products: Regulatory framework, hospital and pharmaceutical circuits in Europe and France. Mebarki M; Madelaine I; Larghero J; de Jorna R Therapie; 2022; 77(2):185-190. PubMed ID: 34895758 [TBL] [Abstract][Full Text] [Related]
10. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453 [TBL] [Abstract][Full Text] [Related]
11. Regulatory Aspects for Approval of Advanced Therapy Medicinal Products in the EU. Fürst-Ladani S; Bührer A; Fürst W; Schober-Ladani N Handb Exp Pharmacol; 2024; 284():367-387. PubMed ID: 37017789 [TBL] [Abstract][Full Text] [Related]
12. Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation. de Wilde S; Veltrop-Duits L; Hoozemans-Strik M; Ras T; Blom-Veenman J; Guchelaar HJ; Zandvliet M; Meij P Cytotherapy; 2016 Jun; 18(6):797-805. PubMed ID: 27068764 [TBL] [Abstract][Full Text] [Related]
13. Surgery Versus ATMPs: An Example From Ophthalmology. Magrelli FM; Merra A; Pellegrini G Front Bioeng Biotechnol; 2020; 8():440. PubMed ID: 32587848 [TBL] [Abstract][Full Text] [Related]
14. Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials. Hanna E; Rémuzat C; Auquier P; Toumi M J Mark Access Health Policy; 2016; 4():. PubMed ID: 27570614 [TBL] [Abstract][Full Text] [Related]
15. Post-marketing authorisation safety and efficacy surveillance of advanced therapy medicinal products in Brazil, the European Union, the United States and Japan. Gomes KLG; da Silva RE; da Silva JB; Bosio CGP; Novaes MRCG Cytotherapy; 2023 Oct; 25(10):1113-1123. PubMed ID: 37436339 [TBL] [Abstract][Full Text] [Related]
16. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products]. Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546 [TBL] [Abstract][Full Text] [Related]
17. Advanced therapy medicinal products in China: Regulation and development. Lu J; Xu L; Wei W; He W MedComm (2020); 2023 Jun; 4(3):e251. PubMed ID: 37125239 [TBL] [Abstract][Full Text] [Related]
18. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine. Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311 [TBL] [Abstract][Full Text] [Related]
19. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products]. Reiss M; Büttel IC; Schneider CK Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535 [TBL] [Abstract][Full Text] [Related]
20. Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving? Boráň T; Menezes-Ferreira M; Reischl I; Celis P; Ferry N; Gänsbacher B; Krafft H; Lipucci di Paola M; Sladowski D; Salmikangas P Hum Gene Ther Clin Dev; 2017 Sep; 28(3):126-135. PubMed ID: 28510497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]